ENTITY
Nippon Shinyaku

Nippon Shinyaku (4516 JP)

56
Analysis
Health CareJapan
Nippon Shinyaku Co., Ltd. manufactures pharmaceutical and health foods products. The Company produces drugs for urinary, nerve, respiratory, and circulatory systems as well as analgesic and anti-inflammatory drugs. Nippon Shinyaku also develops synthetic anti-bacterial agents.
more
bullishNippon Shinyaku
12 Mar 2025 00:30

Nippon Shinyaku (4516 JP): Strong 9MFY25 Numbers; FY25 Guidance Raised; Regular Launches Remain Key

​Nippon Shinyaku sees high single-digit revenue and profit growth in 9MFY25, with Viltepso and Uptravi driving sales increase. FY25 sales guidance...

Logo
389 Views
Share
bearishNippon Shinyaku
27 Dec 2024 13:31

Nippon Shinyaku (4516 JP): Unfavorable Patent Verdict; Company Vows to Fight Back

​US court orders Nippon Shinyaku to pay $115M for patent infringement on Sarepta Therapeutics' DMD drug Vyondys 53. This will significantly impact...

Logo
552 Views
Share
27 Apr 2025 00:30

APAC Healthcare Weekly (April 27)- Sillajen, Akeso, Innovent Biologics, CSL, Daiichi Sankyo, Lupin

SillaJen got FDA nod for clinical trial indication expansion. FDA approves Akeso’s first drug. Innovent’s cancer drug was approved in China....

Logo
496 Views
Share
06 Apr 2025 00:30

APAC Healthcare Weekly (April 6)- Nippon Shinyaku, Shionogi, Beigene, Celltrion, Mesoblast, Lupin

Nippon Shinyaku and Shionogi are filing for new drugs. Beigene dropped a phase 3 oncology asset. Mesoblast is about to start treatment with...

Logo
576 Views
Share
09 Mar 2025 00:30

APAC Healthcare Weekly (Mar 9)- Daiichi Sankyo, Kyorin Pharma, Celltrion, Zydus Lifesciences, Biocon

APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...

Logo
564 Views
Share
x